

ESMO Advanced Course on PARP Inhibition: Therapeutic Applications in Oncology

PROGRAMME

**ESMO
ADVANCED COURSE**

**BARCELONA SPAIN
29-30 OCTOBER 2024**

Co-Chairs

Elena Castro, Spain

Isabelle Ray-Coquard, France

ESMO ADVANCED COURSE PROGRAMME

PARP INHIBITION: THERAPEUTIC APPLICATIONS IN ONCOLOGY

A shared and organ specific view on different cancer locations

Barcelona, Spain
29-30 October 2024

CO-CHAIRS

Elena Castro, Spain
Isabelle Ray-Coquard, France

SPEAKERS

Fabrice André, France
Talia Golan, Israel
Intidhar Labidi-Galy, Switzerland
Christopher Lord, United Kingdom
Joaquin Mateo, Spain
Iain McNeish, United Kingdom
Natacha Naoun, France
Koen Van De Vijver, Belgium

LEARNING OBJECTIVES

- To get an overview on transversal thematic for dedicated pathway to improve competencies
- To understand the basics of DNA repair machinery and the role of PARP
- To share knowledge by experts from organ specific experiences
- To cross compare clinical experience and safety of PARPi in different tumour types
- To understand the mechanisms of resistance and how they are similar or differ among various models
- To learn about the development of PARP inhibition in cancer treatment
- To learn about experiences from each other to improve knowledge in the field of PARPi use and development
- To identify the challenges of PARP inhibition: Overcoming PARPi resistance and future research

ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Tuesday, 29 October 2024

09:00-09:10 **Welcome and opening**

10' Welcome and opening
Elena Castro, ES and Isabelle Ray-Coquard, FR

09:10-10:45 **Session 1 – General concepts**

Chairs: Iain McNeish, UK and Isabelle Ray-Coquard, FR

20' Defects in DNA repair mechanisms across tumour types
Natacha Naoun, FR

20' Targeting DNA repair pathways and PARPi Mechanism of Action
Christopher Lord, UK

20' Molecular biomarkers predicting PARPi efficacy
Intidhar Labidi-Galy, CH

20' Primary versus secondary resistance to PARPi
Iain McNeish, UK

15' Discussion

10:45-11:15 Coffee break

11:15-13:10 **Session 2 – Recent advances in PARP inhibition results in approved indications and other models**

Chairs: Fabrice André, FR and Elena Castro, ES

20' Ovarian cancer
Isabelle Ray-Coquard, FR

20' Breast cancer
Fabrice André, FR

20' Prostate cancer
Elena Castro, ES

20' Pancreatic cancer
Talia Golan, IL

20' Other models
Natacha Naoun, FR

15' Discussion

13:10-14:10 Lunch

14:10-15:40 **Session 3 – Comparing efficacy of PARP inhibition across tumour types**

Chairs: Joaquin Mateo, ES and Isabelle Ray-Coquard, FR

25' Shared experience of PARPi in the metastatic setting: Prostate and ovary examples
Elena Castro, ES and Iain McNeish, UK

25' Rationale and development of PARPi adjuvant versus advanced or relapse: Ovary and breast examples
Fabrice André, FR and Isabelle Ray-Coquard, FR

20' What did we learn from Phase I trials with PARPi?
Joaquin Mateo, ES

20' Discussion

- 15:40-16:10** *Coffee break*
- 16:10-17:05** **Session 4 – Clinical practices in routine**
 Chairs: Elena Castro, ES and Koen van De Vijver, BE
- 20' Testing optimization in clinical practice
Koen Van De Vijver, BE
 - 20' Toxicity management cross vision
Intidhar Labidi-Galy, CH
 - 15' Discussion
- 17:05-17:55** **Session 5 – Future directions of PARP inhibition**
 Chairs: Christopher Lord, UK and Isabelle Ray-Coquard, FR
- 20' Future directions
Christopher Lord, UK
 - 20' New designs, new combinations and new indications exploring the benefit of PARPi
Joaquin Mateo, ES
 - 10' Discussion
- 20:00** *Networking dinner*

Wednesday, 30 October 2024

- 09:00-12:30** **Workshop sessions**
- Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotational basis)
- 15' Introduction based on clinical cases **presented by speakers**
 - 40' Discussion
 - 5' Break
- Workshop 1** Clinical case on prostate cancer including PARPi therapy
60' Elena Castro, ES
- Workshop 2** Clinical case on breast cancer including PARPi therapy
60' Fabrice André, FR
- 11:00-11:30** *Coffee break*
- Workshop 3** Clinical case on ovarian cancer including PARPi therapy
60' Isabelle Ray-Coquard, FR
- 12:30-12:45** **Feedback on the workshops from each group**
Natacha Naoun, FR
- 12:45-13:00** **Synthesis and wrap-up**
Elena Castro, ES and Isabelle Ray-Coquard, FR
- 13:00-14:00** *Lunch*